Design and synthesis of sulfonamide derivatives of pyrrolidine and piperidine as anti-diabetic agents

Type 2 diabetes (T2D) is a lifestyle disease affecting millions of people worldwide. Various therapies are available for the management of T2D and dipeptidyl peptidase-IV (DPP-IV) inhibition has emerged as a promising therapy for the treatment of type 2 diabetes (T2D). Here we report design, synthesis and in vitro efficacy of sulfonamide derivatives of pyrrolidine and piperidine as anti-diabetic agents. Amongst all the compounds synthesized in this series, 9a, is the most potent (IC50 = 41.17 nM). Various sulfonamide derivatives of pyrrolidine and piperidine have been synthesized and their in-vitro enzyme inhibition studies for anti-diabetic activity has been carried out. [Display omitted] •Synthesis of sulfonamide derivatives of pyrrolidine and piperidine.•Docking of the most potent compound 9a and Vildagliptin.•In-vitro anti-diabetic studies.